Key result
Growth hormone replacement therapy during the transition period plays a relevant role in bone maturation, metabolism, and body composition, though uncertainties remain regarding re-testing and optimal dosages.
Why the study?
Clinical practice remains difficult and uncertain regarding persistent growth hormone deficiency after reaching final stature, including identifying who should undergo re-testing, replacement therapy, criteria for therapeutic success, and relationship with cancer survival.
This review clarifies clinical, diagnostic, and therapeutic aspects of managing growth hormone deficiency during the transition period from adolescence to adulthood.
GH in transition may optimize peak bone mass and metabolism; leaves open standardized protocols and RCTs.
The role of growth hormone (GH) during childhood and adulthood is well established. Once final stature is reached, GH continues to act during the transition, the period between adolescence and adulthood in which most somatic and psychological development is obtained. The achievement of peak bone mass represents the most relevant aspect of GH action during the transition period; however, equally clear is its influence on body composition and metabolic profile and, probably, in the achievement of a complete gonadal and sexual maturation. Despite this, there are still some aspects that often make clinical practice difficult and uncertain, in particular in evaluating a possible persistence of GH deficiency once final stature has been reached. It is also essential to identify which subjects should undergo re-testing and, possibly, replacement therapy, and the definition of unambiguous criteria for therapeutic success. Moreover, even during the transition phase, the relationship between GH substitution therapy and cancer survival is of considerable interest. In view of the above, the aim of this paper is to clarify these relevant issues through a detailed analysis of the literature, with particular attention to the clinical, diagnostic and therapeutic aspects.
No takes yet. Share an insight, caveat, or question.
Spaziani et al. (2021) conducted a review in Growth hormone deficiency during the transition period. Growth hormone replacement therapy was evaluated. Growth hormone replacement therapy during the transition period plays a relevant role in bone maturation, metabolism, and body composition, though uncertainties remain regarding re-testing and optimal dosages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: